Alimta Mesothelioma Indication: Response Not Acceptable Endpoint, FDA Says
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Response is not an acceptable primary endpoint for approval in mesothelioma, FDA said in review documents for Lilly’s oncologic agent Alimta.